6th Meeting of the European Society of Oncological Urology (ESOU)

16-18 January 2009, Istanbul, Turkey

ESOU is a full member of the EAU Section Office
Dear Colleagues and Guests,

It is our great pleasure to welcome you all in Istanbul for the 6th Meeting of European Society of Oncological Urology (ESOU). We are excited to see old friends and make new ones while enjoying a highly prestigious scientific atmosphere blended with a unique mixture of cultural heritage of many civilisations for thousands of years and traditional hospitality.

We are in a phase of fast transition in oncological urology both in surgical and medical treatment methods. Introduction of laparoscopy followed by robotic surgery in urological armamentarium resulted in major changes in our daily surgical practice. Consequently, the quality of traditional open surgery has also been improved due to more intense efforts of surgeons to match the attributed advantages of new techniques. During the same period, medical community witnessed a revolution in the field of oncology in general and urological oncology in particular with the introduction of “targeted therapy”. Renal cancers are the primary target of these new agents, mostly suitable for oral use, for the time being, however there are many reasons for other malignancies of the urogenital tract to benefit from such drugs as well.

This era of new developments set the scene for the 6th ESOU Meeting in Istanbul. As reflected by the exciting scientific program and contribution of a highly prestigious international faculty, this meeting promises to become another milestone of ESOU tradition.

Participants will also have the opportunity to enjoy the marvellous city of Istanbul in all sense, which is at the crossroad of many civilisations for thousands of years.

We are looking forward to meet you in Istanbul for the 6th Meeting of ESOU and we will do our best to make this event an extraordinary one both scientifically and socially.

With our best and personal regards,

Prof. Levent Türkeri  
Local Organiser  
ESOU Board member

Prof. Vincent Ravery  
ESOU Chairman
Scientific Programme

Friday, 16 January 2009

08.45 - 09.00 Opening and welcome
L. Türkeri, Istanbul (TR)

09.00 - 09.20 Turkish Uro-Oncology Society lecture: Management of high risk localised prostate cancer
H. Özen, Ankara (TR)

09.20 - 12.30 Prostate cancer - Part I
Treatment of low volume localised prostate cancer
Chairs: V. Ravery, Paris (FR)
B. Djavan, Brussels (BE)

09.20 - 09.50 Active surveillance: Is the available evidence satisfactory?
(interactive voting)
Pro: F. Hamdy, Sheffield (GB)
Con: E. Klein, Cleveland (US)

09.50 - 09.55 Q & A

09.55 - 10.25 Focal therapy will be the future treatment modality
(interactive voting)
Pro: J. De La Rosette, Amsterdam (NL)
Con: A. Zlotta, Toronto (CA)

10.25 - 10.30 Q & A

10.30 - 10.50 Coffee break

10.50 - 11.05 Characteristics of localised prostate cancer in which radiation therapy is the only option
M. Roach, San Francisco (US)

11.05 - 11.10 Q & A

11.10 - 11.25 Surgery is and will be the standard treatment in localised prostate cancer
E. Klein, Cleveland (US)

11.25 - 11.30 Q & A

11.30 - 12.30 Panel: The best surgical approach to treat localised prostate cancer
(video discussion with interactive voting)
Moderator: B. Djavan, Brussels (BE)
Open surgery: E. Klein, Cleveland (US)
Laparoscopic surgery: C. Eden, Basingstoke (GB)
Robotic surgery: F. Bladou, Paris (FR)

Videos to be presented:
1. To control DVC and transection of urethra
2. NVB preservation
3. Bladder neck management
4. Urethro-vesical anastomosis

12.30 - 14.00 Lunch

14.00 - 14.40 Prostate cancer - Part II
Advanced prostate cancer
Chairs: A. Heidenreich, Cologne (DE)
A. Bertaccini, Bologna (IT)

14.40 - 14.55 Critical target evaluation of radiotherapy: Whole pelvis or prostate only?
(interactive voting)
Pro: M. Roach, San Francisco (US)
Con: E. Klein, Cleveland (US)

14.55 - 15.00 Q & A
15.00 - 15.15  IMRT and hypofractionation: Did they improve the efficacy of radiotherapy in prostate cancer over conventional radiotherapy with hormones?  
M. Bolla, Grenoble (FR)

15.15 - 15.20  Q & A

15.20 - 15.40  Coffee break

15.40 - 17.50  Prostate cancer - Part III  
Challenges in prostate cancer  
Chairs: P. Hammerer, Braunschweig (DE)  
S. Brewster, Oxford (GB)

15.40 - 15.55  Prostate cancer: To treat or not to treat?  
P-A. Abrahamsson, Malmö (SE)

15.55 - 16.00  Q & A

16.00 - 16.20  Centres of excellence and certification programmes in prostate cancer: the road to the future  
M. Peyromaure, Paris (FR)

16.20 - 17.10  Panel: Postoperative management in patients with adverse pathological features (interactive voting)

Moderator: H. van Poppel, Leuven (BE)  
Adjuvant radiotherapy: H. Payne (GB)  
Radiotherapy: D. Mitropoulos, Athens (GR)  
Hormones only: I. Romics, Budapest (HU)

16.20 - 17.10  Panel: Postoperative management in patients with adverse pathological features (interactive voting)

Moderator: H. van Poppel, Leuven (BE)  
Adjuvant radiotherapy: H. Payne (GB)  
Radiotherapy: D. Mitropoulos, Athens (GR)  
Hormones only: I. Romics, Budapest (HU)

17.10 - 17.25  Role of chemotherapy in non-metastatic hormone-refractory prostate cancer  
J. Bellmunt, Barcelona (ES)

17.25 - 17.30  Q & A

17.30 - 17.45  Controversies in chemotherapy of metastatic hormone refractory prostate cancer  
S. Bavbek, Istanbul (TR)

17.45 - 17.50  Q & A
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 - 08.55</td>
<td>EORTC-GU lecture: Update on the recent data retrieved from EORTC GU group studies</td>
<td>T. De Reijke, Amsterdam (NL)</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>08.55 - 09.00</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00 - 10.20</td>
<td>Urothelial carcinoma - Part I Challenges in non-muscle invasive disease</td>
<td>R. Montironi, Ancona (IT)</td>
<td>Moderator: M. Brausi, Modena (IT) Intravesical chemotherapy with or without device assistance (EMDA/ Thermochemotherapy): R. Colombo, Milan (IT) Cystectomy: W. Månsson, Lund (SE)</td>
</tr>
<tr>
<td>10.40 - 11.20</td>
<td>Debate: Treatment after failure of initial BCG therapy (interactive voting)</td>
<td></td>
<td>Moderator: M. Kuczyk, Hanover (DE)</td>
</tr>
<tr>
<td>13.30</td>
<td>Close</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Sunday, 18 January 2009

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairs</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 - 10.00</td>
<td><strong>Testis cancer</strong></td>
<td>Chairs: Ç. Çal, Izmir (TR) A. Govorov, Moscow (RU)</td>
<td>G. Janetschek, Linz (AT)</td>
</tr>
<tr>
<td>08.30 - 08.45</td>
<td><strong>The best management option for stage I seminoma</strong></td>
<td>G. Janetschek, Linz (AT)</td>
<td>G. Pizzocaro, Milan (IT)</td>
</tr>
<tr>
<td>08.45 - 08.50</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.50 - 09.05</td>
<td><strong>Consequences of missed nodes during RPLND and how to avoid it?</strong></td>
<td>G. Pizzocaro, Milan (IT)</td>
<td></td>
</tr>
<tr>
<td>09.05 - 09.10</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.10 - 10.00</td>
<td><strong>Debate: Best surgical approach for nerve-sparing RPLND in stage I disease</strong></td>
<td>Moderator: A. Heidenreich, Cologne (DE)</td>
<td>G. Janetschek, Linz (AT) Open surgery is the best: G. Pizzocaro, Milan (IT) Laparoscopic surgery is better: G. Janetschek, Linz (AT)</td>
</tr>
<tr>
<td>10.00 - 10.20</td>
<td><strong>Coffee break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.20 - 12.10</td>
<td><strong>Renal cancer</strong></td>
<td>Chairs: H. Özen, Ankara (TR) G. Mickisch, Bremen (DE)</td>
<td></td>
</tr>
<tr>
<td>10.20 - 10.50</td>
<td><strong>Small renal masses: Is it safe to manage by active surveillance?</strong></td>
<td>Yes: M. Remzi, Vienna (AT) No: Z. Kirkali, Izmir (TR)</td>
<td></td>
</tr>
<tr>
<td>10.50 - 10.55</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.55 - 11.10</td>
<td><strong>Prognostic factors: Does it really matter if new drugs for targeted therapy will be used?</strong></td>
<td>S. Baltaci, Ankara (TR)</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>11.10 - 11.15</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.15 - 11.40</td>
<td><strong>Surgical treatment of locally advanced disease with caval thrombus: Indications for extracorporeal circulation, technical details and clinical outcomes</strong></td>
<td>D. Jacqmin, Strasbourg (FR)</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>11.40 - 11.45</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.45 - 12.05</td>
<td><strong>Treatment of advanced/metastatic renal cancer: A revolution?</strong></td>
<td>H. Van Poppel, Leuven (BE)</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>12.05 - 12.10</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.10</td>
<td><strong>Closing remarks and invitation to 7th ESOU Meeting in 2010</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
General Information

Accommodation
The meeting venue is the Ceylan InterContinental Hotel which is located in the most central part of Istanbul, Taksim. Accommodation can be booked through the housing agency at esouistanbul2009@toles.com.tr. T +90 212 241 5907 F +90 212 241 5902 Alternatively you can visit the ESOU site at www.uroweb.org/meetings-events to download an accommodation form.

Certificate of attendance
Participants who wish to receive a certificate of attendance are invited to collect this at the registration desk after the last session on Sunday, 18 January 2009.

CME accreditation
The 6th ESOU Meeting is accredited within the EU-ACME programme by the European Board of Urology in compliance with the EBU/UEMS regulations. Participants in the EU-ACME programme and active EAU members receive 1 credit point per hour with a maximum of 6 credit points per day and 18 credit points for an entire event. A total of 14 points have been accredited to the 6th ESOU meeting. In order to acquire these credits, please have your EU-ACME card scanned at the registration desk or fill in your EU-ACME registration number of your certificate of attendance and fax it to the EU-ACME Office (Fax: +31 (0)26 389 0848).

For more information please contact the EU-ACME Office at: eu-acme@uroweb.org. The meeting will also be accredited by various National Urological Societies. A list of CME accreditation points will be published in the programme book.

EAU ID card
The EAU has introduced the EAU ID Card which will function as entrance badge to all EAU Congresses and Meetings. The EAU ID Card replaces the paper congress badge. Besides ensuring quick collection of your registration documents at all EAU Congresses and Meetings, the other benefits include: Quick on-site registration, automatic registration of EU-ACME credit points and easy printing of certificates of attendance. Please do not forget to bring your EAU ID Card to all upcoming EAU Congresses and Meetings!

Insurance
The organisers do not accept liability for any personal damage. Participants are strongly advised to arrange their own personal insurance.

Language
All sessions will be conducted in English. No translation will be provided.

Meeting venue
The meeting will be held in:
Ceylan InterContinental
Asker Oca i Cad. No: 1
Taksim 34435
Istanbul, Turkey
T + 90 212 368 4444
F + 90 212 368 4499
http://istanbul.intercontinental.com.tr
**Registration**  
The registration fee includes access to the scientific programme, coffee breaks, lunch on Friday, conference bag and programme book.

To register online, please visit:  
http://registrations.uroweb.org

<table>
<thead>
<tr>
<th></th>
<th>Before 1 December 2008</th>
<th>After 1 December 2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>EAU members</td>
<td>€ 250</td>
<td>€ 350</td>
</tr>
<tr>
<td>Non EAU members</td>
<td>€ 350</td>
<td>€ 450</td>
</tr>
<tr>
<td>EAU resident</td>
<td>€ 125</td>
<td>€ 150</td>
</tr>
<tr>
<td>Non EAU resident</td>
<td>€ 150</td>
<td>€ 175</td>
</tr>
</tbody>
</table>

Cancellation of registration should be notified to the congress secretariat in writing prior to 1 December 2008. Cancellation fees are € 50 before 1 December 2008. No refunds are possible after 1 December 2008.
Faculty
P-A. Abrahamsson, Malmö (SE)
S. Baltaci, Ankara (TR)
S. Bavbek, Istanbul (TR)
J. Bellmunt, Barcelona (ES)
A. Bertaccini, Bologna (IT)
F. Bladou, Paris (FR)
M. Bolla, Grenoble (FR)
M. Brausi, Modena (IT)
S. Brewster, Oxford (GB)
Ç. Çal, Izmir (TR)
X. Cathelineau, Paris (FR)
R. Colombo, Milan (IT)
J. De La Rosette, Amsterdam (NL)
T. De Reijke, Amsterdam (NL)
B. Djavan, Brussels (BE)
C. Eden, Basingstoke (GB)
T. Esen, Istanbul (TR)
J. Fitzpatrick, Dublin (IE)
A. Govorov, Moscow (RU)
F. Hamdy, Sheffield (GB)
P. Hammerer, Braunschweig (DE)
R. Hautmann, Ulm (DE)
A. Heidenreich, Cologne (DE)
S. Holmang, Gothenburg (SE)
D. Jacqmin, Strasbourg (FR)
G. Janetschek, Linz (AT)
Z. Kirkali, Izmir (TR)
E. Klein, Cleveland (US)
M. Kuczyk, Hanover (DE)
G. Lueddecke, Giessen (DE)
W. Månsson, Lund (SE)
L. Martínez-Piñeiro, Madrid (ES)
G. Mickisch, Bremen (DE)
D. Mitropoulos, Athens (GR)
R. Montironi, Ancona (IT)
H. Özen, Ankara (TR)
H. Payne, London (GB)
M. Peyromaure, Paris (FR)
G. Pizzocaro, Milan (IT)
V. Ravery, Paris (FR)
M. Roach, San Francisco (US)
M. Remzi, Vienna (AT)
I. Romics, Budapest (HU)
M. Schoenberg, Baltimore (US)
E. Solsona, Valencia (ES)
G. Thalmann, Berne (CH)
L. Türkeri, Istanbul (TR)
H. Van Poppel, Leuven (BE)
A. Zlotta, Toronto (CA)

ESOU Board
M. Brausi, Modena (IT)
S. Brewster, Oxford (GB)
B. Djavan, Brussels (BE)
A. Govorov, Moscow (RU)
P. Hammerer, Braunschweig (DE)
A. Heidenreich, Cologne (DE)
M. Kuczyk, Hanover (DE)
L. Martínez-Piñeiro, Madrid (ES)
G. Mickisch, Bremen (DE)
V. Ravery, Paris (FR)
L. Türkeri, Istanbul (TR)
A. Zlotta, Toronto (CA)

This meeting is supported by an unrestricted educational grant from: